DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20191208

Lactate dehydrogenase levels in preeclampsia and its correlation with maternal and perinatal outcome

Anjali Gupta, Nirmala Bhandari, Simmi Kharb, Meenakshi Chauhan

Abstract


Background: Hypertensive disorder of pregnancy occurs in approximately 6-8% of all pregnancies. The most serious consequences for the mother and the baby are the result of preeclampsia and eclampsia. Lactate Dehydrogenase (LDH) is an intracellular enzyme. Recently LDH has been suggested as potential marker to predict severity of pre-eclampsia. The objective of the present study was to compare the serum lactate dehydrogenase levels in women with preeclampsia and normal pregnant women and to correlate lactate dehydrogenase levels with maternal and perinatal outcome in preeclampsia.

Methods: An observational prospective study was conducted on 200 antenatal women attending the labour room emergency. Women with singleton pregnancy and cephalic presentation, from 28 weeks onwards were enrolled in the study. Out of 200, 100 were normal pregnant women and 100 were preeclamptic women. Serum LDH levels were measured in all women and maternal and perinatal outcome was assessed in terms of LDH levels.

Results: Higher levels of LDH was observed in pregnant women with preeclampsia (627.38±230.04 IU/l) as compared to normal pregnant women (224.43±116.61 IU/l). The maternal complications were found to be maximum in women with LDH > 800 IU/l.  Abruption was the most common complication. The perinatal mortality and neonatal deaths were found to have significant correlation with high LDH levels.

Conclusions: Maternal and perinatal complications were associated with higher LDH levels in preeclampsia patients. Serum LDH levels can be offered to all patients of preeclampsia and can be used to predict the prognosis of preeclampsia.


Keywords


Maternal outcome, Lactate dehydrogenease, Preeclampsia, Perinatal outcome

Full Text:

PDF

References


Lain KY, Roberts JM. Contemporary concepts of the pathogenesis and management of preeclampsia. Jama. 2002;287(24):3183-6.

Jan AK, Jamil M. Management of Pre-Eclampsia and Eclampsia. JPMI 2000;14(1):7-19.

Vigil P. Maternal deaths due to eclampsia and HELLP syndrome. Int J Gynaecol Obstet 2009;104(2):90-4.

Sibai BM. Maternal and perinatal outcome in 254 consecutive cases. Am J Obstet Gynecol 1990;163(3):1049-54.

Sibai BM, Sarinoglu C, Mercer BM. Pregnancy outcome after eclampsia and long-term prognosis. Am J Obstet Gynecol 1992;166(6):1757-61.

Nodler J, Moolamalla SR, Ledger EM, Nuwayhid BS, Mulla ZD. Elevated antiphospholipid antibody titers and adverse pregnancy outcomes: analysis of a population-based hospital dataset. BMC Pregnancy Childbirth. 2009;9(1):11.

Gynecology and Obstetrics preeclampsia. 2016. Available at: https://www.nhp.gov.in/disease/gynaecology-and-obstetrics/preeclampsia.

Tsoi SCM, Zheng J, Xu F. Differential expression of lactate dehydrogenase isozymes (LDH) in human placenta with high expression of LDH-A4 isozyme in the endothelial cells of pre-eclampsia villi. Placenta 2001;22(4):22-6.

Burd LI, JONES JR MD, Simmons MA, Makowski EL, Meschia G, Battaglia FC. Placental production and foetal utilisation of lactate and pyruvate. Nature. 1975;254(5502):710.

Qublan HS, Amarun V, Bateinen O, Al-Shraideh Z, Tahat Y, Awamleh I, et al. LDH as biochemical marker of adverse pregnancy outcome in severe preeclampsia. Med Sci Monit 2005;11(8):393-7.

Lu H, Forbes RA, Verma A. Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J Biol Chem. 2002;277(26):23111-5.

Lu H, Dalgard CL, Mohyeldin A, McFate T, Tait AS, Verma A. Reversible inactivation of HIF-1 prolyl hydroxylases allows cell metabolism to control basal HIF-1. J Biol Chem 2005;280(51):41928–39.

Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003;9(6):677-84.

Semenza GL. HIF-1 and mechanisms of hypoxia sensing. Curr Opin Cell Biol 2001;13(2):167-71.

Kamath R, Nayak R, Shantharam M. Serum Uric acid level in preeclampsia and its correlation to maternal and fetal outcome. Int J Biomed Res 2014;5(1):22.

Jaiswar SP, Amrit G, Rekha S, Natu SN, Mohan S. Lactic dehydrogenase: A biochemical marker for preeclampsia–eclampsia. J Obstet Gynaecol India 2011;61(6):645-8.

Hazari NR, Hatolkar VS, Munde SM. Study of serum hepatic enzymes in preeclampsia. Int J Curr Med Appl Sci 2014;2(1):1-8.

Gandhi M, Chavda R, Saini HB. Comparative study of serum LDH and uric acid in hypertensive versus normotensive pregnant woman. Int J Biomed Res 2015;6(1):25-8.

Demir C, Evruke C, Ozgunen FT, Urunsak IF, Candan E, Kadayifci O. Factors that influence morbidity and mortality in severe preeclampsia, eclampsia and hemolysis, elevated liver enzymes, and low platelet count syndrome. Saudi Med J. 2006;27(7):1015-8.

Sarkar PD, Sogani S. Evaluation of serum lactate dehydrogenase and gamma glutamyl transferase in preeclamptic pregnancy and its comparison with normal pregnancy in third trimester. Int J Res Med Sci. 2013;1(4):365-8.

Umasatyasri Y, Vani I, Shamita P. Role of LDH (lactate dehydrogenase) in preeclampsia eclampsia as a prognostic marker: An observational study. IAIM. 2015;2(9):88-93.

Bhave NV, Shah PK. A correlation of lactate dehydrogenase enzyme levels in pregnancy induced hypertensive disorders with severity of disease, maternal and perinatal outcome. Int J Reprod Contracept Obstet Gynecol 2017;6(10):4302-8.

Mary VP, Chellatamizh M, Padmanaban S. Role of serum LDH in preeclampsia as a prognostic factor – a cross sectional case control study in tertiary care hospital. Int J Reprod Contracept Obstet Gynecol 2017;6(2):595-8.